CEL-SCI CORPORATION Adjustments to Additional Paid in Capital, Other
CEL-SCI CORPORATION (CVM) reported Adjustments to Additional Paid in Capital, Other of -$4.67 million for the 12-month period ending 2017-09-30, per its 10-K filed 2018-12-19.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2018-12-19
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for the quarter ending 2013-09-30 was -$4.20M.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for the quarter ending 2013-06-30 was $0.00.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for the quarter ending 2012-09-30 was $0.00.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for the quarter ending 2012-06-30 was $0.00.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for fiscal 2017 was -$4.67M.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for fiscal 2016 was -$8.72M.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for fiscal 2015 was -$8.46M.
- CEL-SCI CORPORATION adjustments to additional paid in capital, other for fiscal 2014 was -$7.79M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month | Adjustments to Additional Paid in Capital, Other 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | -$4.67M 10-K · filed 2018-12-19 | ||||
| 2016-09-30 | -$8.72M 10-K · filed 2017-12-29 | ||||
| 2015-09-30 | -$8.46M 10-K/A · filed 2017-12-11 | ||||
| 2014-09-30 | -$7.79M 10-K/A · filed 2017-12-11 | ||||
| 2013-09-30 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | -$4.20M derived: sum of 2 quarters · filed 2015-12-11 | -$4.20M 10-K · filed 2015-12-11 | $0.00 10-K · filed 2013-12-27 | |
| 2013-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 | ||||
| 2012-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | -$122.37K derived: sum of 3 quarters · filed 2013-12-27 | -$122.37K 10-K · filed 2013-12-27 | |
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | -$122.37K derived: sum of 2 quarters · filed 2013-08-09 | -$122.37K 10-Q · filed 2013-08-09 | -$122.37K derived: sum of 4 quarters · filed 2013-12-27 | |
| 2012-03-31 | -$122.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-10 | -$122.37K 10-Q · filed 2013-05-10 | -$122.37K derived: sum of 3 quarters · filed 2013-12-27 | -$122.37K derived: sum of 4 quarters · filed 2013-12-27 | |
| 2011-12-31 | $0.00 10-Q · filed 2012-02-09 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | $0.00 derived: sum of 3 quarters · filed 2013-12-27 | -$141.22K derived: sum of 4 quarters · filed 2013-12-27 | |
| 2011-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | -$141.22K derived: sum of 3 quarters · filed 2013-12-27 | -$202.83K 10-K · filed 2013-12-27 | |
| 2011-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-09 | -$141.22K derived: sum of 2 quarters · filed 2012-08-09 | -$202.83K 10-Q · filed 2012-08-09 | -$202.83K derived: sum of 4 quarters · filed 2012-12-14 | |
| 2011-03-31 | -$141.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-05-10 | -$202.83K 10-Q · filed 2012-05-10 | -$202.83K derived: sum of 3 quarters · filed 2012-12-14 | ||
| 2010-12-31 | -$61.62K 10-Q · filed 2012-02-09 | -$61.62K derived: sum of 2 quarters · filed 2012-12-14 | |||
| 2010-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-14 | -$5.51M 10-K · filed 2012-12-14 | |||
| 2010-06-30 | -$5.51M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |